GenMark planning $60 million follow-on

Molecular diagnostics company GenMark Diagnostics Inc. (NASDAQ:GNMK) proposed late Monday to raise up to $60 million in a follow-on underwritten by JPMorgan. GenMark has 510(k) approval from FDA for its cystic fibrosis (CF) genotyping, warfarin sensitivity, thrombophilia risk and respiratory viral panel tests for use on its XT-8 System, an automated molecular diagnostic platform. ...